Peer-Reviewed Publication
Open Forum Infect Dis2025;12(1):ofaf021.January 1, 2025Journal Article
Coronavirus Disease 2019 (COVID-19) Real World Data Infrastructure: A Big-Data Resource for Study of the Impact of COVID-19 in Patient Populations With Immunocompromising Conditions.
James M Crawford1, Lynne Penberthy2, Ligia A Pinto3, Keri N Althoff4, Magdalene M Assimon5, Oren Cohen6, Laura Gillim6, Tracy L Hammonds7, Shilpa Kapur2, Harvey W Kaufman8, David Kwasny7, Jean W Liew9, William A Meyer8, Shannon L Reynolds5, Cheryl B Schleicher1, Suki Subbiah10, Catherine Theruviparampil5, Zachary S Wallace11, Jeremy L Warner12,13, Suhyeon Yoon14, Yonah C Ziemba1
1Northwell, Department of Pathology and Laboratory Medicine, New Hyde Park, New York, USA.
2Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
3Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
4John Hopkins Bloomberg School of Public Health, Department of Epidemiology, Baltimore, Maryland, USA.
5Aetion Inc, New York, New York, USA.
6Laboratory Corporation of America, Burlington, North Carolina, USA.
7HealthVerity, Philadelphia, Pennsylvania, USA.
8Quest Diagnostics, Secaucus, New Jersey, USA.
9Boston University Chobanian and Avedisian School of Medicine, Section of Rheumatology, Boston, Massachusetts, USA.
10Louisiana State University Health Sciences Center, Section of Hematology/Oncology, New Orleans, Louisiana, USA.
11Massachusetts General Hospital, Division of Rheumatology, Allergy, and Immunology, Boston, Massachusetts, USA.
12Brown University, Department of Medicine, Providence, Rhode Island, USA.
13Rhode Island Hospital, Providence, Rhode Island, USA.
14Integrated Data Sciences Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
BACKGROUND: We developed a United States-based real-world data resource to better understand the continued impact of the coronavirus disease 2019 (COVID-19) pandemic on immunocompromised patients, who are typically underrepresented in prospective studies and clinical trials.
METHODS: The COVID-19 Real World Data infrastructure (CRWDi) was created by linking and harmonizing de-identified HealthVer…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans